Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + sintilimab + SOX
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib + sintilimab + SOX is a combination regimen used as conversion therapy for patients with initially unresectable, locally advanced or metastatic gastric cancer (GC) or gastroesophageal junction cancer (GEJC). Fruquintinib is an oral, highly selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1/2/3), which inhibits tumor angiogenesis. Sintilimab is a monoclonal antibody targeting programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. The SOX regimen consists of S-1 (an oral fluoropyrimidine derivative) and oxaliplatin (a platinum-based chemotherapeutic agent), both of which are cytotoxic agents commonly used in gastrointestinal cancers. This combination leverages the synergistic effects between antiangiogenic therapy, immunotherapy, and chemotherapy to improve resectability rates and clinical outcomes in advanced gastric cancer[6][8].
- Brand names
- ElunateTyvytEloxatin
- Other names
- Fruquintinib + Sintilimab + SOXFruquintinib + Sintilimab + S-1 + Oxaliplatin
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on fruquintinib + sintilimab + SOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + sintilimab + SOX.